CREBBP and classic Hodgkin lymphoma: However, cHL patients with mutated CREBBP presented a shorter PFS (mean PFS: 39.9 months; 95% CI: 21.4–58.4 months) in comparison with patients with wild-type CREBBP (mean PFS: 55.5 months; 95% CI: 41.1–69.9 months) (Figure 5).